⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DBVT News
DBV Technologies S.A.
DBV Technologies to Participate in Upcoming March Investor Conferences
globenewswire.com
DBVT
Form 8-K
sec.gov
DBVTF
DBVT
DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting
globenewswire.com
DBVT
Allergy Immunotherapy Market to Reach $4.9 billion by 2033 Globally, at 10.4% CAGR: Allied Market Research
prnewswire.com
DBVT
DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting
globenewswire.com
DBVT
DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit
globenewswire.com
DBVT
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026
globenewswire.com
DBVT
DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing
globenewswire.com
DBVT
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
globenewswire.com
DBVT
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
globenewswire.com
DBVT